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Background: Surgery followed by adjuvant chemotherapy has been the standard of care for the treatment of
stage III colon cancer since the early 1990’s. Despite this, large proportions of patients do not receive adjuvant
chemotherapy. We aimed to identify physicians’ and patients’ reasons for treatment decisions.
Methods: A retrospective population based study was conducted that included all surgically treated stage III colon
cancer patients diagnosed in Alberta between 2002 and 2005 who had an oncologist-consult to discuss post-
surgical treatment options. Patient demographics and stage were obtained from the Alberta Cancer Registry. Chart
reviews were conducted to extract treatment details, the oncologists’ reasons for not recommending
chemotherapy, and patients’ reasons for refusing chemotherapy. The number and proportion of patients who were
not recommended or refused chemotherapy were calculated.
Results: A total of 613 patients had surgery followed by an oncologist-consult. Overall, 168 (27%) patients did not
receive chemotherapy. It was not recommended for 111 (18%) patients; the most frequent reason was presence of
one or more co-morbidities (34%) or combination of co-morbidity and age or frailty (22%). Fifty-eight (9%) patients
declined chemotherapy, 22% of whom declined due to concerns about toxicity.
Conclusion: Some co-morbidities are clinical indications for not receiving adjuvant chemotherapy, however, the
high percentage of patients who were not recommended adjuvant chemotherapy due to co-morbidities according
to clinical notes but who had a low Charlson co-morbidity score suggests variation in practice patterns of
consulting oncologists. In addition, patients’ reasons for refusing treatment need to be systematically assessed to
ensure patients’ preferences and treatment benefits are properly weighed when making treatment decisions.Background
Treatment guidelines for stage III colon cancer that in-
clude post-surgical (adjuvant) chemotherapy have existed
for twenty years [1]. They are based on the results of clin-
ical trials that compared adjuvant chemotherapy following
surgery versus surgery alone [2-4]. Clinical trials demon-
strated a relative risk reduction of 40% for recurrence and
33% for mortality [3]. Despite these evidence-based treat-
ment guidelines, several studies conducted in the United
States and Canada have shown that a large proportion of* Correspondence: marcy.winget@albertahealthservices.ca
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reproduction in any medium, provided the orpatients with stage III colon cancer do not receive adju-
vant chemotherapy [5-11].
The healthcare system in the province of Alberta,
Canada, is publicly funded and administered; standard
treatments and corresponding visits to specialists are free.
Treatment for cancer patients, other than surgery, is orga-
nized and coordinated provincially. In order to receive
adjuvant chemotherapy, a cancer patient must first have a
consultation with an oncologist to discuss treatment
options. During the consultation visit, the oncologist may
not recommend chemotherapy and/or the patient may
refuse the recommended treatment. Reasons chemother-
apy may not be initiated, therefore, are: 1) the patient was
not referred to an oncologist; 2) the patient did not attend
the consultation after being referred; 3) the oncologist did
not recommend chemotherapy; or 4) the patient refusedral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
El Shayeb et al. BMC Research Notes 2012, 5:269 Page 2 of 8
http://www.biomedcentral.com/1756-0500/5/269the recommended chemotherapy. There are six cancer
facilities that offer oncologist-consults and about 25 oncol-
ogists conduct almost all the consultations for colorectal
cancer patients.
We recently reported [11] that 20% of patients diagnosed
with stage III colon cancer did not have a consultation with
an oncologist to discuss adjuvant chemotherapy after surgi-
cal removal of their tumor. Thirty-seven percent of those
who had a consultation did not receive adjuvant chemo-
therapy within 12 weeks of surgery, as recommended by
treatment guidelines [12]. Older age, co-morbidities, region
of residence, and median household income were signifi-
cantly associated with not having a consultation, while
older age and co-morbidities were associated with not
receiving adjuvant chemotherapy [11]. Here we report a
follow-up to that study, a population-based chart review on
all patients who had a consultation with an oncologist, in
order to: 1) determine the proportion of patients who did
not receive chemotherapy due to the oncologist not recom-
mending treatment and the proportion of patients who
refused the treatment and 2) identify and describe the
reasons the oncologists gave for not recommending adju-
vant chemotherapy, rather than just associated factors, and
the patients’ reasons for refusing it.
Methods
Study population
All residents of Alberta who were diagnosed with histo-
logically confirmed stage III colon adenocarcinoma in
years 2002 to 2005 were identified from the Alberta
Cancer Registry. The Alberta Cancer Registry, initiated
in 1942, is a member of the North American Association
of Comprehensive Cancer Registries and has a proven
record of high quality data [13]. Stage was based on the
American Joint Committee on Cancer Tumor, Node,
and Metastasis (AJCC TNM) staging [14]. Stage III
colon cancer refers to cancer that has spread to the re-
gional lymph nodes but not spread to distant organs.
Patients were included if they had surgical removal of
the tumor followed by a consultation with an oncologist
to discuss post-surgery treatment options. Patients were
excluded if they were treated outside of the province or
had another cancer within 6 months of their colorectal
cancer diagnosis.
Date of consultation with an oncologist to discuss post-
surgical treatment options was obtained from electronic
cancer medical records, which have been in place since
2002. Based on previous quality assurance activities, all
consultations within six months of diagnosis were initially
identified to be a potential consultation to discuss post-
surgical treatment options [15]. Progress notes for all
patients who did not have a consultation within 6 months
of diagnosis were also reviewed to ensure that all patients
with appropriate consultations were included. Althoughavailable electronically, progress notes are based on dicta-
tions which are not standardized.
The study was reviewed and approved by Alberta
Cancer Board Research Ethics Board.
Chart review
A chart review was conducted to extract information
related to the discussion of adjuvant chemotherapy and
the ultimate treatment decision. Specifically, the follow-
ing information was abstracted: 1) whether the physician
recommended chemotherapy; 2) the reason(s) the on-
cologist did not recommend chemotherapy; 3) whether
the patient initiated chemotherapy; and 4) the reason(s)
patients refused chemotherapy. The reasons for not
recommending and for refusing chemotherapy were
identified a priori and are listed in Tables 1 and 2. The
definitions and rules used for selecting each reason are
also listed. To ensure consistency in data extraction and
interpretation, three reviewers (ME, AS, MW) independ-
ently abstracted a random sample of 50 charts. Answers
were compared and discrepancies discussed and
resolved. The reasons for not recommending or refusing
chemotherapy and their corresponding definitions were
modified for clarification, as needed.
Demographic factors and co-morbidity scores
In addition to being the primary source for identify-
ing the study population, the Alberta Cancer Registry
was also the source for the following demographic
data: gender; age; region of residence at diagnosis;
and year of diagnosis. The patient’s postal code at
diagnosis was used to calculate the driving distance
to the nearest cancer center using the driving direc-
tion link from the internet Yellow Pages© (http://
www.yellowpages.ca), as previously described [11].
Neighborhood-level socioeconomic data from the
2001 Canadian census were also obtained to describe
the patient cohort. Variables included median annual
household income, percentage of people living alone,
percentage not graduated from high school, and per-
centage employed.
Modified Charlson co-morbidity scores were calcu-
lated using an updated version of the Deyo et al.[16]
method that was developed by Quan et al.[17] Co-
morbidity scores were calculated using diagnosis codes
obtained from two provincial hospital databases: the
Ambulatory Care Classification System and the Dis-
charge Abstracts Database. These databases contain
dates of visits/admissions/discharge, diagnosis codes,
and procedure codes for all hospital outpatient and in-
patient visits, respectively, in the province. Modified
Charlson co-morbidity scores were calculated using
diagnosis codes that occurred within one year prior to
each patient’s colon cancer diagnosis; diagnosis coding
Table 1 Definitions of oncologists’ reasons for not recommending chemotherapy
Reasons oncologists did not recommend
adjuvant chemotherapy
Definition
Medical complications of surgery Any medical incident during or just following surgery (e.g. myocardial infarction, stroke)
Surgical complications of surgery Any surgery related complication (e.g. delayed wound healing, wound infection, abscess)
Co-morbidities A medical condition or chronic disease preceding the onset of cancer and
perceived by oncologist as a contraindication for chemotherapy (e.g. coronary heart disease,
heart failure, kidney or liver failure)
Frailty/Performance status Generalized weakness or poor physical performance status
Pharmacological concern Potential drug-drug interaction between the adjuvant chemotherapeutic regimens and other
drugs a patient is using for a chronic or incidental medical condition. Potential complication
or adverse event of chemotherapy in a susceptible patient (e.g. vasospasm in a patient
susceptible to coronary heart disease)
No social network or support Lack of social, emotional, or physical support
Age Patient age was the reason or one of the reasons for not recommending chemotherapy
Disease progression Progression of the cancer to stage IV by the time the patient had a consultation with
the oncologist and/or prior to receiving post-surgical treatment
Other Reasons stated other than those listed above (e.g. non-conclusive staging at the time of consult)
Unclear Reason(s) for not recommending chemotherapy are vague and not clearly stated
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Diseases version 9- Clinical Modification (ICD-9-CM)
and the International Classification of Diseases version
10-Canada (ICDM-10-CA).
Statistical analysis
The number and proportion of patients who refused,
were not recommended or received adjuvant chemother-
apy were calculated by the demographic characteristics
included in the study. Chi-square tests were calculated
to determine statistical differences in patient distribu-
tions across the three chemotherapy receipt/non-receipt
categories. The number and proportion of patients who
were not recommended chemotherapy by their oncolo-
gist or who refused chemotherapy were calculated by
reason for not recommending or refusing adjuvant
chemotherapy, respectively. Some reasons were com-
bined due to small numbers.Table 2 Definitions of patients’ reasons for refusing adjuvant
Reasons patients refused adjuvant
chemotherapy
Definition
Toxicity concerns A perceived potential toxic
Co-morbidities A medical condition or chro
barrier to tolerating chemo
failure, kidney or liver failure
Transportation Difficulty reaching the treat
transportation or cost of tra
Age Patient age was the reason
have lived long enough, pe
No social network or support Lack of social, emotional, o
Other Reasons stated other than t
Unclear Reason(s) for refusing chemThe frequencies of the main reasons recorded in pro-
gress notes for not recommending chemotherapy by
oncologists were cross-tabulated with patient age at diag-
nosis and co-morbidity scores. This allows comparison
between the major stated reasons oncologists did not rec-
ommend adjuvant chemotherapy and the major factors
found to be associated with not receiving adjuvant chemo-
therapy in our previous study [11] which included the
same patient population. Analyses were conducted using
Stata SE version 10, StataCorp., Texas, USA.
Results
There were 722 residents of Alberta who were diagnosed
with stage III colon adenocarcinoma in the years 2002 to
2005 of which 618 patients had a consultation with an
oncologist to discuss post surgical adjuvant treatment.
Following the chart review, five patients were excluded
for the following reasons: two patients were treatedchemotherapy
ity side effect (e.g. hair loss, excessive nausea and vomiting).
nic disease preceding the onset of cancer and perceived by patient as a
therapy (e.g. coronary heart disease, heart
)
ment facility due to either unavailability of means of
nsportation
or one of the reasons for refusing chemotherapy (e.g. patient felt they
rceived limited life expectancy)
r physical support
hose listed above (e.g. fear of injections)
otherapy are vague and not clearly stated
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one patient’s consultation was not related to post-
surgical treatment. The analysis included the remaining
613 patients.
Figure 1 shows the proportion of patients for whom
chemotherapy was not recommended by their oncologist
and the proportion of patients that refused adjuvant
chemotherapy in relation to the timing of their consult-
ation with respect to their surgery. Overall 27% (168) of
the patients did not commence adjuvant chemotherapy.
It was not recommended for 111 (18%) patients and 58
(9%) patients refused adjuvant chemotherapy. Only one
patient decided to pursue adjuvant chemotherapy des-
pite not being recommended by the oncologist. Of inter-
est is that 26 patients had a consultation more than
12 weeks after their surgery, the maximum time that
should elapse before initiating adjuvant chemotherapy as
per treatment guidelines [12]; 16 of these patients were
recommended chemotherapy and 12 of them initiated it.
Delayed or late consult was not the reason for not
recommending adjuvant chemotherapy to any of
patients who had a consultation more than 12 weeks
post-surgery.
Table 3 presents the distribution of patient characteristics
by refusal, recommendation and receipt of chemotherapy.
Older patients were less likely to be recommended chemo-
therapy and were more likely to refuse it if recommended
(p< 0.0001). Patients in the northern regions of the prov-
ince were more likely to refuse chemotherapy whereas
















Oncologist-consult < 12 
weeks after surgery
587 (96%)
Figure 1 Proportion of patients with stage III colon cancer in Alberta
chemotherapy.(9=0.03). Chemotherapy recommendation and/or patient
refusal were related to the neighborhood income (p=0.01),
percent living alone (p< 0.0001), and percent employed
measures (p=0.04). Patient gender, year of diagnosis,
distance from a cancer center, and neighborhood education
level were not associated with receipt/refusal/recommenda-
tion of chemotherapy.
The recorded reasons in progress notes that oncologists
did not recommend adjuvant chemotherapy to the 111
patients are presented in Table 4. The most common rea-
son was the presence of co-morbidities (62 patients). Pres-
ence of co-morbidities was the only reason for not
recommending chemotherapy to 38 (34%) patients and
was combined with age, frailty, or another reason for 24
(22%) patients. Frailty and age, alone or combined, were
reasons for not recommending adjuvant chemotherapy to
22 (19%) patients. Medical or surgical complications of
surgery were the reason oncologists did not recommend
adjuvant chemotherapy to 12 (11%) patients. Seven (6%)
patients were not recommended chemotherapy due to
disease progression.
Fifty-eight (9%) patients refused adjuvant chemother-
apy even though it was recommended; Table 5 presents
the reasons for refusal. The most common recorded
reason for refusing adjuvant chemotherapy by patients
was toxicity concerns (13 patients), however, reason for
refusal was unclear for over half the patients that refused
(34 patients).
Table 6 shows the results of the cross-tabulation be-
















Oncologist-consult > 12 
weeks after surgery
26 (4%)
who were not recommended and/or refused adjuvant
Table 3 Relationship between refusal, recommendation, and receipt of adjuvant chemotherapy and characteristics of








Patient Characteristics n (%)1 n (%)1 n (%)1 n (%)2
Total 58 (9) 110 (18) 445 (73) 613 (100)
Gender: P = 0.84
Female 27 (9) 48 (17) 208 (73) 283 (46)
Male 31 (9) 62 (19) 237 (72) 330 (54)
Age at diagnosis: P<0.0001
<65 10 (4) 11 (4) 232 (92) 253 (41)
65-69 5 (7) 6 (8) 60 (85) 71 (12)
70-74 11 (11) 13 (13) 76 (76) 100 (16)
≥ 75 32 (17) 80 (42) 77 (41) 189 (31)
Geographical regions: P = 0.03
South 4 (9) 10 (22) 31 (69) 45 (7)
Calgary 8 (4) 40 (21) 143 (75) 191 (31)
Central 7 (7) 18 (19) 72 (74) 97 (16)
Edmonton 29 (13) 35 (16) 157 (71) 221 (36)
North 10 (17) 7 (12) 42 (71) 59 (10)
Distance from cancer facility P = 0.97
< 90 km 49 (10) 94 (18) 369 (72) 512 (84)
90-180 km 5 (8) 9 (15) 47 (77) 61 (10)
> 180 km 4 (10) 7 (18) 29 (73) 40 (7)
Year of diagnosis: P = 0.10
2002 8 (6) 26 (18) 109 (76) 143 (23)
2003 22 (13) 23 (14) 124 (73) 169 (28)
2004 17 (12) 26 (18) 100 (70) 143 (23)
2005 11 (7) 35 (22) 112 (71) 158 (26)
Median annual household income* P=0.01
< $37881 14 (12) 29 (25) 75 (64) 118 (20)
$37881 – $51057 15 (10) 29 (19) 110 (71) 154 (26)
$51058 - $67124 19 (12) 29 (19) 107 (69) 155 (26)
> $67124 9 (5) 20 (12) 143 (83) 172 (28)
% Living alone* P<0.0001
< 7% 20 (7) 36 (13) 218 (80) 274 (46)
7 – 24% 29 (19) 53 (19) 196 (71) 278 (46)
> 24% 8 (17) 18 (38) 21 (45) 47 (8)
Patient Characteristics n (%)1 n (%)1 n (%)1 n (%)2
% Not graduated from high school* P = 0.50
< 27% 29 (9) 51 (16) 234 (75) 314 (52)
> 27% 28 (10) 56 (20) 201 (71) 285 (48)
% Employed* P=0.04
< 60% 16 (10) 40 (25) 101 (64) 160 (27)
60 – 71% 18 (8) 36 (17) 160 (75) 211 (35)
> 71% 23 (10) 31 (14) 174 (76) 228 (38)
1 – Row percentage.
2 – Column percentage.
*14 patients had missing data for neighborhood-level variables based on 2001 Canadian census.
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Table 4 Physicians’ reasons for not recommending adjuvant chemotherapy to patients diagnosed with stage III colon
cancer in Alberta between 2002 and 2005
Single Reason n (%) Multiple Reasons n (%)
Co-morbidity only 38 (34) Co-morbidity and age 11 (10)
Frailty only 8 (7) Co-morbidity and frailty 7 (6)
Age only 6 (5) Co-morbidity and other reason 6 (6)
Complication of surgery* 12 (11) Age and frailty 8 (7)
Disease progression 7 (6) Other - multiple reasons 3 (3)
Other - single reason 5 (5)
Total 76 (68) Total 35 (32)
*Either surgical or medical complication of surgery described in Table 1.
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extracted from the patient charts (co-morbidity, age, and
frailty) with the actual patient age at diagnosis and co-
morbidity score calculated from administrative data; this
comparison was done to see how well the factors of ac-
tual age and co-morbidity score corresponded to those
factors as reasons for not recommending adjuvant
chemotherapy. Of those patients for whom adjuvant
chemotherapy was not recommended due to presence of
co-morbidity according to patient charts, 22 of 62
patients (35%) had a co-morbidity score of 0 calculated
from the administrative data. Conversely, 94 (19%) of
the 502 patients for whom chemotherapy was recom-
mended had a co-morbidity score of 2 or more. 44
(70%) of the patients who were not recommended adju-
vant chemotherapy due to co-morbidities were 75 years
or older at the time of their diagnosis. All of the patients
who were not recommended adjuvant chemotherapy
due to age were 75 years or older. Similarly, 21 of the 24
“frail” patients were 75 years or older.
Discussion
Previous studies that have evaluated adherence to treat-
ment guidelines for stage III colon cancer and barriers
to receiving them have used administrative data or sur-
veys [5,7-11,18-21]. These study designs identify associa-
tions but not causality. We conducted a chart review to
identify the documented reasons or causes for non-
receipt of adjuvant chemotherapy rather than associated
independent variables or factors.Table 5 Stage III colon cancer patients’ reasons for
refusing adjuvant chemotherapy





Toxicity concerns 13 (22)
Age 4 (7)
Co morbidities 3 (5)
Other 4 (7)Our results show that two thirds of the patients who
did not initiate chemotherapy did not because their on-
cologist did not recommend it to them; the primary rea-
sons recorded in patient charts were co-morbidity
followed by age and frailty, respectively. The remaining
third refused the treatment despite being recommended.
Other studies have found that the oncologist’s recom-
mendation is the main factor determining whether or
not a patient receives chemotherapy and that patients
tend to follow their oncologist’s recommendation
regarding adjuvant chemotherapy [22,23]. Patient prefer-
ences and their perception towards their outcomes and
survival probabilities also have a large impact on
decision-making [24].
22% of patients refused chemotherapy due to toxicity
concerns. More importantly, there was not a clear rea-
son for refusal in 59% of the patients who declined
chemotherapy. These patients tended to leave the con-
sultation visit undecided and ask their oncologist for
time to consider their options. Ultimately, they either
never replied (even when phone messages were left by
nursing staff ) or called to decline without giving specific
reasons. We found that a chart review, therefore, was
not an effective way of identifying reasons for patient re-
fusal of treatment. Patient surveys or interviews are
likely more efficient, however, they are challenging, as
cancer patients are often asked to complete surveys for
various purposes (e.g., patient satisfaction, research stud-
ies); it is important not to overly burden these ill
patients. Another challenge with patient surveys is the
selection bias based on the degree of illness in the
responders so the results may not be generalizable.
Co-morbidity alone or combined with other reasons was
the most frequently documented reason patients were not
recommended adjuvant treatment in our study, however,
presence of co-morbidities, such as heart disease, did not
universally preclude patients from being recommended to
receive adjuvant chemotherapy. Two recent large, geo-
graphically diverse, surveys conducted among surgical and
medical oncologists examined how different hypothetical
clinical scenarios, varying patient age and co-morbidities,
Table 6 Agreement between primary reasons for not recommending chemotherapy extracted from patient charts vs.
patient age and Charlson co-morbidity index
Oncologists’ reasons for not recommending adjuvant chemotherapy
Co-morbidities







0 22 (35) 15 (60) 11 (46) 48
1 14 (23) 5 (20) 6 (25) 25
2 or more 26 (42) 5 (20) 7 (29) 38
Age
<65 6 (10) 0 0 6
65-69 3 (5) 0 0 3
70-74 9 (15) 0 3 (13) 12
≥ 75 44 (70) 25 (100) 21 (87) 90
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for patients with stage III colon cancer [18,19]. The sur-
veys found that physicians agree on recommending
chemotherapy for healthy young individuals, but differ
widely for older patients with or without co-morbidities;
the recommendations differed also by the severity of the
co-morbidity (mild, moderate, or severe) regardless of pa-
tient age. Consistent with these surveys, our results
showed inconsistency in recommendations based on pa-
tient age and presence of co-morbidities. Adjuvant chemo-
therapy, however, provides a significant survival benefit for
colon cancer patients with chronic diseases including
heart failure, chronic obstructive pulmonary diseases, and
diabetes [25]. Efforts are needed to improve consensus
amongst oncologists on the value of adjuvant chemother-
apy in currently under-treated patient groups, particularly
those with co-morbidities.
To further investigate the way physicians integrate the
presence of co-morbidities and its interaction with age in
making a treatment recommendation, we cross-tabulated
the frequency of these reasons extracted from our chart re-
view to assess the degree to which actual age and co-
morbidity scores corresponded to them. The co-morbidity
index (a tool that has been validated as a reliable index in
predicting one-year survival) [16,17] was found to be 0 in
22 patients for whom co-morbidity was the reason for not
being recommended adjuvant chemotherapy. On the flip
side, 94 patients for whom chemotherapy was recom-
mended had a co-morbidity index of 2 or more, indicating
the significant variation amongst oncologists in Alberta in
their perception of the importance of co-morbidities in
recommending adjuvant chemotherapy. A limitation to this
comparison is that we did not extract details on co-
morbidities that patients had regardless of whether they
were recommended adjuvant chemotherapy. This would
have allowed for a more direct comparison to the co-
morbidity scores as well as better assess variation in prac-
tice based on specific co-morbidities and their severity.The discrepancy between chart review data and admin-
istrative data can also be attributed to the way in which
the co-morbidity score is calculated. Diagnoses for 17 con-
ditions that are known to increase the risk of death in the
year following hospitalization are included in the calcula-
tion of the co-morbidity score. If a patient was not seen in
a hospital as an inpatient or an outpatient in the year prior
to their diagnosis, no co-morbidities would be identified;
similarly, if a patient was seen in a hospital for reasons un-
related to the co-morbidities used to calculate the co-
morbidity score, for instance, a broken leg, it is possible
that all existing co-morbidities would not be coded in the
visit.
Two population-based studies have shown a survival ad-
vantage in standard clinical practice in patients with stage
III colon cancer treated with chemotherapy within 12 weeks
of surgery; co-morbidity was not significantly associated
with survival in one of them [26], however, it was associated
with survival in the other one [27].
Conclusion
Despite the fact that most studies that have evaluated ad-
herence to treatment guidelines for patients with stage III
colon cancer have found that patient age is the factor most
strongly associated with not receiving adjuvant chemother-
apy, presence of one or more co-morbidities is the primary
documented reason patients with stage III colon cancer are
not recommended to receive adjuvant chemotherapy in Al-
berta, Canada. Given the large percentage of patients who
did not receive adjuvant treatment, the inconsistency of
whether chemotherapy was recommended to patients with
co-morbidities, and the poor correlation between the co-
morbidity score and co-morbidity as the reason adjuvant
chemotherapy was not recommended, further studies and
discussion to better define patients who are clinically ap-
propriate to receive adjuvant chemotherapy are needed.
Specifically, studies that evaluate the relationship between
survival, adjuvant chemotherapy and co-morbidities in
El Shayeb et al. BMC Research Notes 2012, 5:269 Page 8 of 8
http://www.biomedcentral.com/1756-0500/5/269patients with stage III colon cancer are needed to inform
development of clearer evidence-based treatment guidelines
and/or improve consensus amongst oncologists.
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